CO5150150A1 - 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales - Google Patents

4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales

Info

Publication number
CO5150150A1
CO5150150A1 CO99081336A CO99081336A CO5150150A1 CO 5150150 A1 CO5150150 A1 CO 5150150A1 CO 99081336 A CO99081336 A CO 99081336A CO 99081336 A CO99081336 A CO 99081336A CO 5150150 A1 CO5150150 A1 CO 5150150A1
Authority
CO
Colombia
Prior art keywords
quinoleincarboxamidas
dihidro
oxo
antiviral agents
substituted
Prior art date
Application number
CO99081336A
Other languages
English (en)
Inventor
Steven Ronald Turner
Suvit Thaisrivongs
Valerie A Vaillancourt
Mark E Schnute
Allen Scott
Joseph Walter Strohbach
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CO5150150A1 publication Critical patent/CO5150150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Un compuesto de fórmula I<EMI FILE="99081336_1" ID="1" IMF=JPEG >en donde,R1 es C1-7alquilo, opcionalmente substituido con hidroxilo o NR4R5; R2 es C1-7alquilo substituido con hidroxilo o NR4R5;R3 es H, F o C1-7 alcoxilo;R4 y R5 conjuntamente con N son un radical heterocíclico de 5 ó 6 miembros que tienen 1-3 heteroátomos seleccionados del grupo formado de nitrógeno, oxígeno y azufre, en el cual el azufre puede estar substituido por uno (1) o dos (2) átomos de oxígeno; y una sal farmacéuticamente aceptable del mismo.
CO99081336A 1999-01-08 1999-12-29 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales CO5150150A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11511399P 1999-01-08 1999-01-08
US13839099P 1999-06-09 1999-06-09
US14061499P 1999-06-23 1999-06-23

Publications (1)

Publication Number Publication Date
CO5150150A1 true CO5150150A1 (es) 2002-04-29

Family

ID=27381602

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99081336A CO5150150A1 (es) 1999-01-08 1999-12-29 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales

Country Status (28)

Country Link
US (1) US6248736B1 (es)
EP (1) EP1140851B1 (es)
JP (1) JP2002534417A (es)
KR (1) KR20010101428A (es)
CN (1) CN1132818C (es)
AT (1) ATE275134T1 (es)
AU (1) AU2158300A (es)
BR (1) BR9916781A (es)
CA (1) CA2353634A1 (es)
CO (1) CO5150150A1 (es)
CZ (1) CZ20012458A3 (es)
DE (1) DE69919897T2 (es)
EA (1) EA004043B1 (es)
ES (1) ES2228162T3 (es)
HK (1) HK1041879A1 (es)
HU (1) HUP0105142A3 (es)
ID (1) ID29452A (es)
IL (1) IL144170A0 (es)
MY (1) MY118904A (es)
NO (1) NO320396B1 (es)
NZ (1) NZ512823A (es)
PE (1) PE20001337A1 (es)
PL (1) PL348769A1 (es)
PT (1) PT1140851E (es)
SK (1) SK8312001A3 (es)
TR (1) TR200101893T2 (es)
TW (1) TW593281B (es)
WO (1) WO2000040563A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US6544990B2 (en) 2001-03-01 2003-04-08 Pharmacia & Upjohn Company Substituted quinolinecarboxamides as antiviral agents
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
AR038294A1 (es) 2002-01-14 2005-01-12 Upjohn Co Oxotieno(3,2-b)piridincarboxamidas como agentes antivirales
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
AR038117A1 (es) 2002-01-14 2004-12-29 Upjohn Co Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida
WO2004019933A1 (en) * 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
AU2003262947A1 (en) * 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
KR100665919B1 (ko) 2002-11-20 2007-03-08 니뽄 다바코 산교 가부시키가이샤 4-옥소퀴놀린 화합물 및 ｈｉｖ 인테그라제 저해제로서의그의 용도
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
EP1650192A4 (en) 2003-07-24 2007-03-21 Astellas Pharma Inc QUINOLONE DERIVATIVE OR SALT THEREOF
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
WO2005112930A1 (en) * 2004-05-21 2005-12-01 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
LT2489659T (lt) 2004-06-24 2018-03-26 Vertex Pharmaceuticals Incorporated Atp rišančios kasetės transporterių moduliatoriai
US20070032522A1 (en) * 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
RS60205B1 (sr) 2005-12-28 2020-06-30 Vertex Pharma Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
EP1978960A4 (en) * 2006-02-01 2009-12-02 Japan Tobacco Inc USE OF 6- (3-CHLORO-2-FLUORBENZYL) -1 - [(2S) -1-HYDROXY-3-METHYLBUTAN-2-YL [-7-METHOXY-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXYLIC ACID OR SALT THEREOF FOR THE TREATMENT OF RETROVIRUS INFECTION
WO2007102512A1 (ja) * 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
DE102008036099B4 (de) 2008-08-04 2014-02-13 Steag Power Saar Gmbh Entstickungsanlage
KR101955863B1 (ko) 2009-03-20 2019-03-07 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
NZ604745A (en) * 2010-08-27 2015-01-30 Gruenenthal Chemie Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
NZ629199A (en) 2012-02-27 2017-01-27 Vertex Pharma Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
PL2909192T3 (pl) 2012-10-16 2017-09-29 Janssen Pharmaceutica Nv Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
BR112016008258A2 (pt) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv moduladores de ror?t de quinolinila
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
JP7273951B2 (ja) 2018-09-12 2023-05-15 ノバルティス アーゲー 抗ウイルス性ピリドピラジンジオン化合物
KR20220070005A (ko) 2019-09-26 2022-05-27 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593810B1 (fr) * 1986-01-24 1988-04-22 Sanofi Sa Derives de la quinoleine, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
EP0550464A1 (en) * 1990-09-07 1993-07-14 Schering Corporation Antiviral compounds and antihypertensive compounds
US5175151A (en) 1990-09-07 1992-12-29 Schering Corporation Antiviral compounds and antihypertensive compounds
EP0531578B1 (en) 1991-09-10 1995-12-20 Agfa-Gevaert N.V. Thermally transferable fluorescent compounds
MX9800922A (es) 1995-08-02 1998-05-31 Darwin Discovery Ltd Quinolonas y su uso terapeutico.
CN1200114A (zh) 1995-10-19 1998-11-25 武田药品工业株式会社 作为gnrh拮抗剂的喹啉衍生物
DK0944619T3 (da) 1996-11-27 2007-02-05 Bristol Myers Squibb Pharma Co Hidtil ukendte integrinreceptorantagonister
CA2309882A1 (en) 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents

Also Published As

Publication number Publication date
IL144170A0 (en) 2002-05-23
NO320396B1 (no) 2005-11-28
EA200100755A1 (ru) 2001-12-24
EA004043B1 (ru) 2003-12-25
NZ512823A (en) 2003-10-31
ID29452A (id) 2001-08-30
BR9916781A (pt) 2001-12-04
PE20001337A1 (es) 2000-11-23
PL348769A1 (en) 2002-06-17
EP1140851B1 (en) 2004-09-01
DE69919897T2 (de) 2005-09-08
MY118904A (en) 2005-02-28
PT1140851E (pt) 2004-12-31
AU2158300A (en) 2000-07-24
US6248736B1 (en) 2001-06-19
JP2002534417A (ja) 2002-10-15
ATE275134T1 (de) 2004-09-15
HK1041879A1 (en) 2002-07-26
NO20013379D0 (no) 2001-07-06
DE69919897D1 (en) 2004-10-07
TW593281B (en) 2004-06-21
ES2228162T3 (es) 2005-04-01
NO20013379L (no) 2001-07-06
CA2353634A1 (en) 2000-07-13
CZ20012458A3 (cs) 2001-12-12
SK8312001A3 (en) 2001-12-03
KR20010101428A (ko) 2001-11-14
CN1332729A (zh) 2002-01-23
EP1140851A1 (en) 2001-10-10
HUP0105142A2 (hu) 2002-04-29
HUP0105142A3 (en) 2002-05-28
CN1132818C (zh) 2003-12-31
TR200101893T2 (tr) 2001-11-21
WO2000040563A1 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
CO5150150A1 (es) 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales
CO5261589A1 (es) Compuestos heterociclicos, su produccion y su utilizacion
ATE402701T1 (de) N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
AP1771A (en) 3&#39;-Prodrugs of 2&#39;-deoxy-?-L-nucleosides.
CO5251404A1 (es) Compuestos antibioticos de azalida
CO5300398A1 (es) Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek
TR200102805T2 (tr) Glikokinaz aktivatörleri
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
UY26093A1 (es) Inhibidores de ap2 de bifenilos que contienen compuestos heterociclicos y metodo
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
CO5180629A1 (es) Pirimidina-2,4,6-ttrionas inhibidores de metaloproteinasas
CO5690130A1 (es) Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento del snc
NO20021395D0 (no) Kinazolinderivater
BRPI0515596A (pt) composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero
NO921609D0 (no) Sulfonamider og deres medisinske anvendelse
CO5261527A1 (es) Eteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
CO5251439A1 (es) Compuestos calciliticos
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
CO5251424A1 (es) Oxazinquinolonas utiles en el tratamiento de infecciones virales
CO5140099A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
ES2038754T3 (es) Agentes antiarritmicos.
PE20011028A1 (es) Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino
ATE253931T1 (de) High density lipoprotein zur bekämpfung von organdysfunktion infolge hämorrhagischem schocks
ATE273985T1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung
ATE271542T1 (de) 2-thiocarbamoyloxy- und 2-carbamoyloxy-derivate von cyclopentyl-heptan(en)säure als therapeutische mittel